RT Journal Article
SR Electronic
T1 First Tissue-Agnostic Drug Approval Issued
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
SP 656
OP 656
DO 10.1158/2159-8290.CD-NB2017-078
VO 7
IS 7
YR 2017
UL http://cancerdiscovery.aacrjournals.org/content/7/7/656.2.abstract
AB The PD-1 inhibitor pembrolizumab received accelerated approval for adult and pediatric patients with solid tumors that are mismatch repair–deficient or microsatellite instability–high. This is the first time the FDA has greenlighted a drug based not on tumor type, but on a common biomarker.